Botvymo® (botensilimab) and Evamplix® (balstilimab) receive separate approvals for use in combination Armenia is the first country to approve marketing authorization of BOT+BAL, following a rigorous review of quality, nonclinical, clinical and pharmacovigilance data Approvals supported by clinical evidence published in peer-reviewed journals and presented at major oncology congresses, including two-year Phase 1b survival findings … Continued